Linda Ohrmund is an Associate Consultant with over thirteen years of experience in small molecule research, diagnostic assay development, and logistics support in the life sciences and tradeshow industries. With Latham BioPharm Group, Ms. Ohrmund works as a project manager monitoring cost, vendors, and schedules.
Ms. Ohrmund was responsible for the diagnostic development, validation and transfer to tech ops of the Anser® IFX and Anser® ADA diagnostic assays. In support of this project, Ms. Ohrmund managed development of proof-of-concept assays, preparation of protein and antibody conjugations, preparation of IP for patents, training of technicians, creation of SOPs, and preparation of validation reports. Ms. Ohrmund also collaborated with academic leaders in the field to screen samples, analyze data, and prepare results for publication using the Anser® platforms.
Ms. Ohrmund worked in small molecule research and development for 5 years. During this time, she served as the IACUC chairperson and performed a wide variety of in vitro and in vivo assays. She collaborated with Vanderbilt to screen activity of novel compounds using IHC, trained peers on proper IHC and ICC techniques, and implemented a mouse model of multiple sclerosis (EAE).
Linda Ohrmund received her Bachelor of Science in Biochemistry and Cell Biology from University of California San Diego.